The cost of the Sputnik V vaccine would be Rs. 995.40 in India. This price has been fixed by Dr. Reddy’s Laboratories, as announced on Friday, May 14, 2021. The original price of the dose is Rs. 948, which becomes Rs. 995.40 after the 5% GST per dose added to it, according to msn.com. The price might be lowered when the supply of the vaccine begins locally.
Effectiveness of the drug:
The drug is reported to be 91.6% effective after the administration of two doses of it. The first dose of this vaccine has already been administered in Hyderabad, as Dr. Reddy’s laboratory mentioned on Friday, May 14, 2021. The Global Head of Custom Pharma Services (Dr. Reddy’s Laboratory), Deepak Sapra, is the first to have received the Sputnik V vaccine in India.
There is also a report from Thursday, May 13, 2021, that the Sputnik V vaccine will be made available next week to all Indians. There will be two billion doses of the vaccine between August and December 2021, as promised by the Central Government. This is a sign of relief when there is a great demand and less supply of the Covaxin and the Covishield. The very first import of the vaccine was made on May 1, 2021. The drug has also got regulatory clearance from Kasauli’s Central Drugs Laboratory on Thursday, May 13, 2021. Let us hope that this reduces the total load on the Covishiled and the Covaxin.
Everything about the Sputnik V vaccine:
The vaccine originates from Russia and has gone through trials in Russia, India, and UAE with a 91.6% efficiency against the coronavirus disease. It received an emergency restricted use in India by the Drugs Controller General of India (DGCI) in April 2021. The drug needs to be administered in two doses (0.5 ml per dose) within a gap period of 21 days. It is stored at -18 degrees Celsius if in liquid form or at 2-8 degrees Celsius in powdered form. The vaccine has also been said to be produced in India from July 2021, and the number to be produced is proposed to be 15.6 crores. The two doses carry different vectors, rAd26 and rAd5, with full-length SARS-CoV-2 glycoprotein and target the coronavirus’s distinctive spikes. It has already been used in 60 different countries with favorable results and is believed to do the same in India.
